{"prompt": "['Trelagliptin-4002', 'Page 63 of 66', 'Version 1.0', 'November 2, 2016', 'consent form and information sheet is revised. The date of obtaining new consent shall be recorded', \"in the study subject's medical record, and a copy of the revised consent form shall be provided to the\", 'study subject.', '15.4', 'Personal information of the study subjects', \"The sponsor or the designee shall affirm the principle of the protection of study subjects'\", 'private/personal information. Throughout this study, study subject ID codes shall be used to link the', \"subject's source data to the sponsor's study database and study-related documents. Limited\", 'information on study subjects such as gender, age, and date of birth may be used within the scope of', 'all applicable laws and regulations for identification of study subjects and confirmation of accuracy', 'of study subject ID code.', 'For verification of the conduct of the study in compliance with this protocol and the Ethical', 'Guidelines for Medical and Health Research Involving Human Subjects, the sponsor shall require', \"the principal investigator to provide the study sponsor's designee, representatives of regulatory\", 'authorities, designated auditors, and committees such as the Ethical Review Board direct access to', \"study subjects' original medical records (source data or documents), including laboratory test results,\", \"admission and discharge records during a subject's study participation, and autopsy reports. The\", 'principal investigator or investigator shall obtain specific authorization of the study subject as part of', \"the informed consent process for access to study subject's original medical records by study\", \"sponsor's designee and representatives of regulatory authorities (see Section 15.3).\", 'When providing a copy of source documents to the sponsor, the principal investigator or investigator', 'shall delete information that may lead to identification of an individual (name and address of study', 'subject, other personal information not recorded on the CRF of the study subject).', '15.5', 'Consultation windows for the study subjects or persons related to the study', 'concerned', 'The principal investigator shall establish a contact service to respond to inquiries concerning this', 'clinical study from study subjects or concerned people. Details of the contacts for inquiries will be', 'described in the informed consent form and information sheet.', '15.6 Financial burden or reward to the study subjects', 'Of the expenses for this clinical study, the sponsor shall offer compensation for medical treatment', 'not covered by health insurance as study expenses. The study subjects shall pay expenses for', 'medical treatment covered by ordinary health insurance.', 'In addition, the principal investigator shall pay expenses such as transportation expenses for', 'participation in this clinical study to the study subjects at each visit from the research funds. Details', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 64 of 66', 'Version 1.0', 'November 2, 2016', 'of the financial burden on the study subjects and rewards shall be described in the informed consent', 'form and information sheet.', '15.7', 'Benefits and inconveniences to the study subjects', '15.7.1 Benefits to study subjects', 'Study subjects can deeply learn their own conditions of type 2 diabetes including such as the change', 'in the QOL associated with the change in treatment approaches and the level of treatment', 'satisfaction, through the study participation', '15.7.2 Inconveniences to study subjects', 'Burdens of study subjects may be increased due to requirements of providing answers to the Basic', 'Information on Study Subject, DTR-QOL Questionnaire and DTSQ, through the study participation.', '15.8', 'Attribution of study results and access rights', '15.8.1 Attribution of study results', 'The study results and data obtained from this study shall belong to the sponsor. In addition,', 'secondary use (meta-analysis, etc.) of the data obtained in this clinical study may be possible if used', 'in such a way that the data shall not be linked to personal identification information.', '15.8.2 Data access rights', 'Access rights for all data and information generated from this study will be given to personnel', 'approved by the sponsor.', '15.9', 'Reporting of results, publication, disclosure, and clinical study registration', 'policy', '15.9.1 Reporting of results, publication and disclosure', 'The principal investigator shall report a written summary of results of the study to the chief', 'executive of the study site and provide the sponsor with all the results and data obtained from the', 'study. Only the sponsor may disclose the study information to other principal investigators,', 'investigators or regulatory authorities during the study period, except when required by laws and', 'regulations. The sponsor shall be responsible for publication of the study protocol and study-related', 'results (including the public web site) except for other cases permitted in the study contract.', 'During the study period and after the end of study, the sponsor or the designee should promptly', 'summarize the results and present it to medical journals and academic conferences, etc. The sponsor', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 65 of 66', 'Version 1.0', 'November 2, 2016', 'may publish any data or information obtained from the study (including data and information', 'provided by the principal investigator) without obtaining agreement of the principal investigator.', 'The principal investigator or the investigator should obtain the prior written approval from the', 'sponsor when publishing the information obtained in this study at an academic conference, etc.', '15.9.2 Clinical study registration', 'To ensure that information on clinical study is made accessible to the public in a timely manner and', 'to comply with applicable laws, regulations, and guidelines, Takeda Pharmaceutical Company', 'Limited shall register all clinical study being conducted in patients around the world at public trial', 'registration sites, including at least the website(s) of ClinicalTrials.gov (and) Japan Pharmaceutical', 'Information Center Clinical Trials Information (JAPIC), before initiation of the clinical study. On', 'such websites, the study location (city, country), study subject recruitment status, and contact', 'information for Takeda Pharmaceutical Company Limited are open to the public.', '15.9.3 Clinical trial results disclosure', 'Takeda Pharmaceutical Company Limited shall post the study results, irrespective of the nature of', 'the results, at the public trial registration site(s) of Clinical Trials.gov (and) JAPIC in accordance', 'with applicable laws and regulations.', '15.10 Insurance and compensation for injury', 'In case of injuries, each study subject in the clinical study must be insured in accordance with the', 'regulations applicable to the study site where the subject is participating. The sponsor or the', 'designee shall buy an insurance policy to compensate for health injury in study subjects.', 'Healthy injury in a study subject will be compensated as specified in the study contract.', 'Compensation-related questions by the principal investigator or investigators should be made to the', 'sponsor or the designee.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 66 of 66', 'Version 1.0', 'November 2, 2016', '16.0 REFERENCES', '1.', 'Treatment Guide for Diabetes 2016-2017. Edited by Japan Diabetes Society. BUNKODO', 'Corp. 2016', '2.', 'Izumi K, Noda M. In order to reduce the interruption of diabetes treatment. Diabetes Frontier.', '2014;25:709-718.', '3.', 'Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance.', 'Diabetes Care. 1997;20:1512-1517.', '4.', 'Yamazaki M, Higo N, Kaneko T, et.al. SGLT2 Inhibitors As the Trigger for Diabetes Care:', 'Reconfirmed Importance of Behavior Modification After Drug Administration. J.Japan', 'Dab.Soc.2015;58:745-752.', '5.', 'Ishii H. Development and psychometric validation of the Diabetes Therapy-Related QOL', '(DTR-QOL) questionnaire. J Med Econ. 012;15:556-563.', '6.', 'Bradley C: Diabetes treatment satisfaction questionnair (DTSQ). In: Handbook of', 'psychology and diabetes (ed. by Bradley C.). Harwood Academic Pubi., Chur, 1994', '7.', 'Ishii H, Bradley C, Riazi A, et al. The Japanese Version of the Diabetes Treatment', 'Satisfaction Questionnaire (DTSQ): translation and clinical evaluation. Journal of Clinical', 'and Experimental Medicine. 2000;192:809-14. (A Japanese Journal published in Japanese)', '8.', 'Sadamoto K, Takamori H, Sadamoto T, et al. Impact of push-through-packages with', 'electronic devices for accurate drug taking. Journal of Scientific and Innovative Research.', '2014;3:288-294.', '9.', 'Report of the Working Group on Conflict of Interest (Ministry of Education, Culture, Sports,', 'Science and Technology dated November 1, 2002)', '10.', 'Guidelines for determining the conflict of interest polity for clinical research (Review group', 'for ethical aspects of clinical study and conflict of interest, March 2006)', '11. Guidelines on the Management of COI in Health and Labor Sciences Research (No. 0331001,', 'science, issued on March 31, 2008, and approved by the Chief of the Health Sciences', 'Division)', '12. Guidelines for management of COI in medical research (COI Committee of Japan', 'Association of Medical Sciences, February 2011)', '13. Common guidelines for conflict of interest (COI) in clinical research (Japanese Society of', 'Internal Medicine, Japan Society of Hepatology, Japanese Circulation Society, Japan', 'Endocrine Society, Japan Diabetes Society, Japanese Respiratory Society, Japanese Society', 'of Hematology, Japanese Society of Allergology, Japanese Association for Infectious', 'Diseases, Japan Geriatrics Society, Aug 2011)', 'CONFIDENTIAL']", "completion": ""}